Clinical Trial Update: TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating whether adding low-dose upadacitinib to a TNF inhibitor improves response in Crohn's disease patients with suboptimal res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Conditions: Crohn Disease (CD) | Phase 4 | Status: RECRUITING